@article{84491b41c70d417daa6ba938ce64f947,
title = "Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions",
abstract = "Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin and joint manifestations affecting approximately 2% of the population. In the first 5 parts of the AmericanAcademy of Dermatology Psoriasis Guidelines of Care, we have presented evidence supporting the use of topical treatments, phototherapy, traditional systemic agents, and biological therapies for patients with psoriasis and psoriatic arthritis. In this sixth and final section of the Psoriasis Guidelines of Care, we will present cases to illustrate how to practically use these guidelines in specific clinical scenarios. We will describe the approach to treating patients with psoriasis across the entire spectrum of this fascinating disease from mild to moderate to severe, with and without psoriatic arthritis, based on the 5 prior published guidelines. Although specific therapeutic recommendations are given for each of the cases presented, it is important that treatment be tailored to meet individual patients' needs. In addition, we will update the prior 5 guidelines and address gaps in research and care that currently exist, while making suggestions for further studies that could be performed to help address these limitations in our knowledge base.",
keywords = "adalimumab, alefacept, biologics, case studies, clinical guidelines for psoriasis, combination therapy, comorbidities, dermatology, etanercept, gaps in knowledge, gaps in research, golimumab, guidelines, inflammation, infliximab, methotrexate, narrowband, phototherapy, psoralen plus ultraviolet A, psoriasis, psoriatic arthritis, skin disease, systemic therapy, therapeutic recommendations, topical treatments, traditional systemic therapy, tumor necrosis factor-alfa, ustekinumab",
author = "Alan Menter and Korman, {Neil J.} and Elmets, {Craig A.} and Feldman, {Steven R.} and Gelfand, {Joel M.} and Gordon, {Kenneth B.} and Alice Gottlieb and Koo, {John Y.M.} and Mark Lebwohl and Leonardi, {Craig L.} and Lim, {Henry W.} and {Van Voorhees}, {Abby S.} and Beutner, {Karl R.} and Caitriona Ryan and Reva Bhushan",
note = "Funding Information: Steven R. Feldman, MD, PhD: Dr Feldman served on the Advisory Board and was investigator and speaker for Galderma, Stiefel, Warner Chilcott, Abbott Labs, and Astellas receiving grants and honoraria; served on the Advisory Board for Photomedex receiving stock options; received grants from National Psoriasis Foundation and Dermatology Foundation, Coria, ASDS, Aventis Pharma Ortho Pharma, Pharmaderm, and Roche Dermatology; was an investigator and speaker for Amgen, Centocor, Connetics, and Genentech receiving grants and honoraria; was a speaker and consultant for Bristol-Myers Squibb Derm receiving grants; a speaker for Novartis and 3M receiving grants; and a consultant and speaker for Bristol-Myers Squibb Derm and Biogenidec receiving grants. He received separate department funding from Acuderm, Advanced Tissue Sciences, Allergan, Aventis, Bristol-Myers Squibb, Combe, Curatek, Ferndale, Fujisawa, Hermal, Hoffman LaRoche, Galderma, Genderm, Glaxo Wellcome, Hill, Janssen, Mayrand, Neostrata, Neutrogena, Novartis, Oclassen, Ortho, Person & Covey, Proctor & Gamble, RJR Nabisco, Schering-Plough, Shelton, SmithKline, Stiefel, 3M, United Catalyst, Upjohn and Wolff Systems. ",
year = "2011",
month = jul,
doi = "10.1016/j.jaad.2010.11.055",
language = "English",
volume = "65",
pages = "137--174",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Elsevier Inc.",
number = "1",
}